Hikma Pharmaceuticals to acquire Xellia Pharmaceuticals' US finished dosage business for $135M cash plus potential $50M, subject to FTC approval.

Hikma Pharmaceuticals to acquire parts of Xellia Pharmaceuticals' US finished dosage form business and assets for $135M cash, with potential $50M contingent consideration. Deal includes a Cleveland facility, R&D center in Zagreb, and a team of experienced R&D professionals. It aims to expand Hikma's injectables portfolio, add RTU products, and increase manufacturing capacity. The acquisition is subject to US FTC approval, and Hikma's 2024 guidance remains unchanged.

June 17, 2024
4 Articles